Reducing Involuntary Movements in Participants With Tardive Dyskinesia
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of
SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe
tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809
following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks
of maintenance with SD-809.